|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 抗生素相关性腹泻的治疗 微生态制剂可能有助于预防显示文摘腹泻是抗生素治疗过程中一种常见的不良作用。5%~30%的患者在抗生素治疗早期或治疗结束后2个月内会发生抗生素相关性腹泻。抗生素相关性腹泻的发生率取决于对腹泻的定义、所使用的抗生素种类和宿主的个体因素。 | FrédéricBarbut Jean Luc Meynard 范洪伟 | 2003 | 英国医学杂志中文版2003，6，1： | 15 |
| 2 | Soluble ST2:A new and promising activity marker in ulcerative colitis显示文摘AIM:To correlate circulating soluble ST2(sST2) levels with the severity of ulcerative colitis(UC) and serum levels of pro-inflammatory cytokines,and to demonstrate the predictive power of sST2 levels for differentiation between active and inactive UC.METHODS:We recruited 153 patients:82 with UC,26 with Crohn's disease(CD) and 43 disease controls [non-inflammatory bowel disease(IBD)].Subjects were excluded if they had diagnosis of asthma,autoimmune diseases or hypertension.The serum levels of sST2 and pro-inflammatory cytokines [pg/mL;median(25th-75th)] as well as clinical features,endoscopic and histological features,were subjected to analyses.The sST2 performance for discrimination between active and inactive UC,non-IBD and healthy controls(HC) was determined with regard to sensitivity and specificity,and Spearman's rank correlation coefficient(r).To validate the method,the area under the curve(AUC) of receiver-operator characteristic(ROC) was determined(AUC,95% CI) and the total ST2 content of the colonic mucosa in UC patients was correlated with circulating levels of sST2.RESULTS:The serum sST2 value was significantly higher in patients with active [235.80(90.65-367.90) pg/mL] rather than inactive UC [33.19(20.04-65.32) pg/mL],based on clinical,endoscopic and histopathological characteristics,as well as compared with non-IBD and HC(P < 0.001).The median level of sST2 in CD patients was 54.17(35.02-122.0) pg/mL,significantly higher than that of the HC group only(P < 0.01).The cutoff was set at 74.87 pg/mL to compare active with inactive UC in a multicenter cohort of patients.Values of sensitivity,specificity,and ability to correctly classify UC,according to activity,were 83.33%,83.33% and 83.33%,respectively.The AUC of the ROC curve to assess the ability of this molecule to discriminate between active vs inactive UC was 0.92(0.86-0.97,P < 0.0001).The serum levels of sST2 in patients with UC significantly correlated with endoscopic and histo-pathological scores(r = 0.76 and r = 0.67,P < 0.0001,respectively),and with the pro-inflammatory cytokine,tumor necrosis factor-α(r = 0.69 and r = 0.61,respectively,P < 0.0001).Interestingly,we found a direct correlation between total intestinal ST2 content and serum levels of sST2,adjusted to endoscopic activity score in patients with mild(r = 0.44,P = 0.004),moderate(r = 0.59,P = 0.002) and severe disease(r = 0.82,P = 0.002).Only patients with inactive UC showed no significant correlation(r = 0.45,P = 0.267).CONCLUSION:sST2 levels correlated with disease severity and inflammatory cytokines,are able to differentiate active from inactive UC and might have a role as a biomarker. | David Díaz-Jiménez Lucía E Núez Caroll J Beltrán Enzo Candia Cristóbal Suazo Manuel varez-Lobos María-Julieta González Marcela A Hermoso Rodrigo Quera | 2011 | World Journal of Gastroenterology2011，17，17： | 8 |
| 3 | New therapeutic opportunities for Hepatitis C based on small RNA显示文摘Hepatitis C virus (HCV) infection is one of the major causes of chronic liver disease, including cirrhosis and liver cancer and is therefore, the most common indication for liver transplantation. Conventional antiviral drugs such as pegylated interferon-alpha, taken in combination with ribavirin, represent a milestone in the therapy of this disease. However, due to different viral and host factors, clinical success can be achieved only in approximately half of patients, making urgent the requirement of exploiting alternative approaches for HCV therapy. Fortunately, recent advances in the understanding of HCV viral replication and host cell interactions have opened new possibilities for therapeutic intervention. The most recent technologies, such as small interference RNA mediated gene-silencing, anti-sense oligonucleotides (ASO), or viral vector based gene delivery systems, have paved the way to develop novel therapeutic modalities for HCV. In this review, we outline the application of these technologies in the context of HCV therapy. In particular, we will focus on the newly defined role of cellular microRNA (miR-122) in viral replication and discuss its potential for HCV molecular therapy. | Qiu-wei Pan Scot D Henry Bob J Scholte Hugo W Tilanus Harry LA Janssen Luc JW van der Laan | 2007 | World Journal of Gastroenterology2007，13，33： | 4 |
| 4 | On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprineor 6-mercaptopurine intolerant IBD patients显示文摘AIM: To determine the tolerability and safety profile of a low-dose maintenance therapy with 6-TG in azathioprine (AZA) or 6-mercaptopurine (6-MP) intolerant inflammatory bowel disease (IBD) patients over a treatment period of at least 1 year.METHODS: Database analysis.RESULTS: Twenty out of ninety-five (21%) patients discontinued 6-TG (mean dose 24.6 mg; mean 6-TGN level 540 pmol/8×108 RBC) within 1 year. Reasons for discontinuation were GI complaints (31%), malaise (15%)and hepatotoxicity (15%). Hematological events occurred in three patients, one discontinued treatment. In the 6-TG-tolerant group, 9% (7/75) could be classified as hepatotoxicity. An abdominal ultrasound was performed in 54% of patients, one patient had splenomegaly.CONCLUSION: The majority of AZA or 6-MP-intolerant IBD patients (79%) is able to tolerate maintenance treatment with 6-TG (dosages between 0.3 and 0.4 mg/kg per d). 6-TG may still be considered as an escape maintenance immunosuppressant in this difficult to treat group of patients, taking into account potential toxicity and efficacy of other alternatives. The recently reported hepatotoxicity is worrisome and 6-TG should therefore be administered only in prospective trials. | Nanne KH de Boer Luc JJ Derijks Lennard PL Gilissen Daniel W Hommes Leopold GJB Engels Sybrand Y de Boer Gijsbertus den Hartog Piet M Hooymans Anja BU M(?)kelburg Barend D Westerveld Anton HJ Naber Chris JJ Mulder Dirk J de Jong | 2005 | World Journal of Gastroenterology2005，11，35： | 4 |
| 5 | Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: A meta-analysis of observational studies显示文摘 | Mathurin Fumery Cao Xiaocang Luc Dauchet Corinne Gower-Rousseau Laurent Peyrin-Biroulet Jean-Frédéric Colombel | 2013 | Journal of Crohn’s and Colitis2013，，： | 3 |
| 6 | Epidemiology of inflammatory bowel diseases: New insights from a French population-based registry (EPIMAD)显示文摘 | Corinne Gower-Rousseau Francis Vasseur Mathurin Fumery Guillaume Savoye Julia Salleron Luc Dauchet Dominique Turck Antoine Cortot Laurent Peyrin-Biroulet Jean Frédéric Colombel | 2012 | Digestive and Liver Disease2012，，： | 3 |
| 7 | Lactic acid bacteria as functional starter cultures for the food fermentation industry显示文摘 | Frédéric Leroy Luc De Vuyst | 2003 | Trends in Food Science & Technology2003，，2： | 2 |
| 8 | Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study显示文摘 | LUC G BARD J M ARVEILER D | 2001 | Atherosclerosis2001，163，2： | 2 |
| 9 | The relevance of size efficiency to biomanipulation theory:a field test under hypertrophic conditions显示文摘 | Steven D Luc D M Nicole P | 1997 | Hydrobiologia1997，360，： | 2 |
| 10 | Connectedness of the efficient point sets in quasiconcave vector maximization显示文摘 | Luc D T | 1987 | Journal of Optimization Theory and1987，122，： | 1 |
| 11 | Apolipoproteins CⅢ and E in apoB-and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction:the ECTIM study显示文摘 | Luc G Fievet C Arveiler D | 1996 | J Lipid Res1996，37，3： | 1 |
| 12 | Biodiversity and identification of sour- dough lactic acid bacteria 显示文摘 | LUC D V MARC V | 2007 | Food Microbiology2007，24，2： | 1 |
| 13 | Mobile phone follow-up of subjects include in a prospective cohort study: unexpected difficulties 显示文摘 | Isabelle P Luc D Laurent B | 2007 | Eur J Epidemiol2007，22，： | 1 |
| 14 | Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease:The PRIME Study显示文摘 | Luc G Arveiler D Evans A | 2003 | Atherosclerosis2003，170，1： | 1 |
| 15 | Structure of the efficient point set显示文摘 | LUC D T | 1985 | Proc Amer Math Soc1985，95，： | 1 |
| 16 | Lipoprotein (a) as a predictor of coronary heart disease : the PRIME Study显示文摘 | Luc G Bard JM Arveiler D | 2001 | Atherosclerosis2001，163，20： | 1 |
| 17 | Interleukin-1 g and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction(PRIME)显示文摘 | Blankenberg S Luc G Ducimetiere P Arveiler D Ferrieres J Amouyel P | 2003 | Circulation2003，108，： | 1 |
| 18 | Contributions of depressivemood and circulating inflammatory markers to coronary heartdisease in healthy European:The prospective epidemiological studyof myocardial infarction(PRIME)显示文摘 | Empana J P Sykes D H Luc G | 2005 | Circulation2005，111，7： | 1 |
| 19 | Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: the PRIME study 显示文摘 | LUC G ARVEILER D EVANS A | 2003 | Therosclerosis2003，170，1： | 1 |
| 20 | Bread, beer and wine: Saccharomyces cerevisiae Diversity reflects human history显示文摘 | Legras J luc Merdinoglu D Cornuet J marie | 2007 | Molecular Ecology2007，16，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员